Describe barriers to care and challenges in the management of AD, SD, and PsO Assess the role of targeting PDE-4 in IMISC pathogenesis and the implications of treatment Evaluate current and emerging topical PDE-4 inhibitors for the treatment of AD, SD, PsO, including their role in the treatment of intertriginous areas and pediatric populations Outline treatment strategies for patients with AD, SD, and PsO that address unmet needs and consider patient goals and non-steroidal topical agents
- Provider:HMP Education
- Activity Link: https://www.hmpeducation.com/program/24-derm-102-2
- Start Date: 2024-12-16 06:00:00
- End Date: 2024-12-16 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
- Commercial Support: Source: Arcutis Biotherapies, Inc. - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: General Surgery
Subscribe
Login
0 Comments
Oldest